Phase 3 Readout~month

Phase 3 Topline: A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone

Indication
Asthma

Other upcoming events for TEVA

Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Eff
Phase 3 ReadoutPhase 3 Topline: Randomized, Multi-Center, Evaluator-Blind, Vehicle-Controlled Study to Evaluate Efficacy and Safety
Phase 3 ReadoutPhase 3 Topline: Randomized, Multi-Center, Evaluator-Blind, Vehicle-Controlled Study to Evaluate Efficacy and Safety
Patent ExpiryPatent/Exclusivity Expiry: AKYNZEO

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone — TEVA Phase 3 Readout | BioSniper